A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Japan Biz of Top 3 Generic Makers in H1 Impacted by GMP Issues, Substitution Demand: Jiho Tally
November 25, 2021
-
BUSINESS Alnylam to File Its Third Drug in Japan 3 Years after Market Entry, Eyes CNS Therapies
November 24, 2021
-
ORGANIZATION 20% of Listed Drugs in Japan, Mostly Generics, Hit by Supply Issues: FPMAJ Survey
November 22, 2021
-
REGULATORY Japan OKs 56 Trillion Yen Stimulus Package, Spells Out Support for Japan-Made Drugs and Vaccines
November 22, 2021
-
BUSINESS Top 4 Wholesalers’ Average Operating Margin at 0.46% on Tough Price Negotiations: H1 FY2021 Earnings
November 22, 2021
-
REGULATORY Japan Panel Discusses Safety, Immunity Rules for Envisaged Emergency Approval Scheme
November 19, 2021
-
REGULATORY Ex-Minister Tamura Says Efficacy/Safety Confirmation Important in Emergency Approval, Wary on Macroeconomic Indexing
November 18, 2021
-
BUSINESS Otsuka’s Eczema Drug, 2 More Products Skip November Listing
November 18, 2021
-
BUSINESS Aducanumab Gets “Negative Trend Vote” in Europe: Biogen/Eisai
November 18, 2021
-
REGULATORY 50 Billion Yen-Plus Peak Sales Projected for Pfizer’s Vynmac, Listing Set for Nov. 25
November 17, 2021
-
COMMENTARY MOF, MHLW Push Conflicting Narratives on Drug Cost Control; Macroeconomic Indexing Is a Major Focus Too
November 16, 2021
-
REGULATORY Japan to Use mRNA Jabs for Boosters, Pfizer Vaccine for Time Being: Panel
November 16, 2021
-
BUSINESS Ono to Pay 28 Billion Yen to Settle Opdivo Feud with Honjo
November 15, 2021
-
REGULATORY Govt to Provide Up to 2 Billion Yen per Oral COVID-19 Drug to Support Development
November 15, 2021
-
BUSINESS Aikomi, Sumitomo Dainippon Eye Therapeutic App Approval for BPSD by 2027
November 12, 2021
-
ORGANIZATION Ex-MHLW Bureau Chief Calls for 6% Adjustment Rate, Frowns on Macroeconomic Indexing; Study Group Launch Next Month
November 11, 2021
-
REGULATORY Japan Approves Pfizer COVID-19 Vaccine for Booster Use
November 11, 2021
-
REGULATORY Japan to Receive 1.6 Million Courses of MSD’s COVID-19 Drug
November 11, 2021
-
BUSINESS Pfizer’s COVID-19 Vaccine Filed for Children 5 to 11 in Japan
November 10, 2021
-
BUSINESS 6 Wholesalers Raided over Suspected Bid-Rigging in Kyushu
November 10, 2021
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…